Voyager Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 08, 2022 at 07:07 am EST
Share
Voyager Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net income was USD 17.62 million compared to net loss of USD 25.14 million a year ago. Basic earnings per share from continuing operations was USD 0.46 compared to basic loss per share from continuing operations of USD 0.67 a year ago. Diluted earnings per share from continuing operations was USD 0.45 compared to diluted loss per share from continuing operations of USD 0.67 a year ago.
For the nine months, net loss was USD 22.78 million compared to USD 76.91 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 2.04 a year ago. Diluted loss per share from continuing operations was USD 0.59 compared to USD 2.04 a year ago.
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Companyâs pipeline includes programs for Alzheimerâs disease, amyotrophic lateral sclerosis (ALS), Parkinsonâs disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreichâs Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimerâs disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.